A catheter system designed to enable more stable delivery of stem cells to heart tissue is showing promise, having demonstrated the safety of transendocardial stem cell injection (TESI) of autologus two different kinds of bone marrow cell therapies in a Phase II trial. BioCardia (San Carlos, California) reported positive 12-month results for the randomized Transendocardial Autologous Cells in Ischemic Heart Failure Trial (TAC-HFT) that used its Helical Infusion Catheter System in the treatment of chronic ischemic cardiomyopathy (ICM).